Journals / Kocatepe Tıp Dergisi / 2015 / Cilt: 16 - Sayı: 1

Non Alkolik Yağlı Karaciğer Hastalığında Güncel Medikal Tedavi

Pages
67–76
Publication Date
2015-05-08
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This paper is focused on the currently treatments for NAFLD

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nonalcoholic fatty liver disease is one of the most prevalent liver disease.
📊
Key Findings & Data:NAFLD is increasing in parallel with the worldwide epidemic of obesity.
💡
Conclusion & Impact:This paper is focused on the currently treatments for NAFLD
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:naykh · güncel · tedavi

Abstract

Nonalcoholic fatty liver disease is one of the most prevalent liver disease. NAFLD is increasing in parallel with the worldwide epidemic of obesity. NAFLD may progress from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. Several evidences suggest that multiple mechanisms including insulin resistance, oxidative stress, inflammation, and genetic factors interact to initiate the development of NAFLD. Despite that there is currently no approved drug therapy for NAFLD, many approaches consider to be beneficial. Insulin sensitizers, antioxidants, antilipidemic drugs and antiinflammatory agents showed promising effects. This paper is focused on the currently treatments for NAFLD

Özet

Non Alkolik Yağlı Karaciğer Hastalığı, en yaygın karaciğer hastalıklarından biridir. NAYKH, obezitenin dünya epidemisiyle paralel olarak artmaktadır. NAYKH, basit yağlanmadan steatohepatite, ileri fibroz ve siroza ilerleyebilir. Kanıtlar; insülin direnci, oksidatif stres ve genetik faktörlerlerin interaksiyonunu içeren çoklu mekanizmaların NAYKH’nın gelişimini başlattığını göstermektedir. Halen onaylanmış bir ilaç tedavisi olmamasına rağmen pek çok yaklaşımın faydalı olabileceği göz önünde bulundurulmalıdır. İnsülin duyarlaştırıcılar, antioksidanlar, antilipidemik ilaçlar ve antiinflamatuar ilaçların faydalı etkileri gösterilmiştir. Bu yazıda NAYKH’ nın mevcut tedavisi ve potansiyel yeni tedaviler üzerine odaklanılmıştır

🔖

Cite This Article

ACAY, A. (2015). Non Alkolik Yağlı Karaciğer Hastalığında Güncel Medikal Tedavi. Kocatepe Tıp Dergisi, Cilt: 16 - Sayı: 1, 67–76. https://ajindex.com/articles/686257

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Sonsuz A. Nonalkolik karaciğer yağlanması. http:// www.ctf.edu.tr/stek/pdfs/58/5807.pdf 23.11.2007. Erişim Jansen PL. Nonalcoholic steatohepatitis. Neth J Med 2004;62(7):217-24.
  2. Durazzo M, Belci P, Collo A, Grisoglio E, Bo S. Focus on therapeutic strategies of nonalcoholic fatty liver disea- se. http://www.medscape.com/viewarticle/474880?s- rc=search Erişim 17.10.2012.
  3. Dabhi A, Brahmbhatt K, Pandya T, Thorat P, Shah M. Nonalcoholic fatty liver disease. JIACM 2008;9(1):36- 41. Hajiaghamohammadi A, Ziaee A, Oveisi S, Masroor H. Effects of metformin, pioglitazone, and silymarin treat- ment on non-alcoholic fatty liver disease: a randomized controlled pilot study. Hepatitis Monthly 2012;12(8):1- 6. Lomonaco R, Chen J, Chen K. An endocrine perspective of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab 2011;2(5):211–4.
  4. Ledinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices 2010;7(6):811-23.
  5. Trappoliere M, Tuccillo C, Federico A, Di Leva A, Niosi M. The treatment of NAFLD. Eur Rev Med Pharmacol Sci 2005;9(5):299-304. Clark J. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40(Sup 1):39-43.
  6. Harrison S, Kadakia S, Lang K, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol. 2002 Nov;97(11):2714-24.
  7. Vajro P, Lenta S, Pignata C et al. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. http://www.ijponline.net/content/pdf/1824-7288- 38-55.pdf doi:10.1186/1824-7288-38-55 Erişim 12.10.2012
  8. Sözen M, Türkay C. Ursodeoksikolik asit için tıbbi endi- kasyonlar ve etki mekanizmaları. http://guncel.tgv.org. tr/journal/39/pdf/100039.pdf Erişim 2011 Grigoreva I. Ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease. Eksp Klin Gastroente- rol 2011;(9):125-31.
  9. Trauner M, Graziadei I. Rewiev article: Mechanism of action and therapeutic application of ursodeoxycholic acid in chronic liver disease. Aliment Pharmacol Ther 1999;13:979-96. Kowdley K. Ursodeoxycholic acid therapy in hepatobili- ary disease. Am J Med 2000;108(6):481-6.
  10. Lindor K, Kowdey K, Heathcote E et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: re- sult of a randomized trial. Hepatology 2004;39(3):770 Vajro P, Veropalumbo C. Citrin deficiency: learn more, and don’t forget to add it to list of neonatal cholestasis and the NASH trash bin. J Pediatr 2010;50(6):578-9. Adam